Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome

The American Academy of Neurology recently held their annual meeting virtually to discuss the latest research in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). This meeting was held April 17th through 22nd,…

Continue Reading Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome
Four New Rare Disease Studies Receive $19 Million in Funding
source: pixabay.com

Four New Rare Disease Studies Receive $19 Million in Funding

The Patient-Centered Outcomes Research Institute (PCORI) has announced that it will be contributing funding for four new studies focused on four different rare diseases. The funding will top out at…

Continue Reading Four New Rare Disease Studies Receive $19 Million in Funding
CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE
source: pixabay.com

CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE

According to a story from BioPortfolio, the biopharmaceutical company GW Pharmaceuticals plc recently announced that its medicine Epidyolex has earned recommendation from the UK National Institute for Health and Care…

Continue Reading CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE
Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies
geralt / Pixabay

Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…

Continue Reading Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years

Cluster Seizures Approximately 1/3 of all epilepsy patients live with uncontrolled seizures. Of these, around 150,000 in the United States alone  experience cluster seizures (otherwise known as acute-repetitive seizures, crescendo…

Continue Reading A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years

The LGS Foundation’s 6th International Conference

  • Post author:
  • Post category:

The Sixth International Conference on LGS (Lennox-Gastaut syndrome) The LGS Foundation's annual international conference is a three day event that is ideally suited for LGS patients and their families, as…

Continue Reading The LGS Foundation’s 6th International Conference

A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases

Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It's just been published that in 2018 they approved a…

Continue Reading A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases

Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated

Two Phase 2 clinical trials called ‘Elektra’ and ‘Arcade’ have been initiated. They will investigate the drug OV935/TAK-935 as a potential treatment for paediatric patients with rare epilepsies. For more…

Continue Reading Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
stevepb / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced
kkolosov / Pixabay

Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced

The organisations Takeda Pharmaceutical Company and Ovid Therapeutics are collaborating over the development of the experimental drug TAK-935/OV935 as a possible treatment for several rare epilepsy syndromes. Takeda has just…

Continue Reading Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced
First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome
7raysmarketing / Pixabay

First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome

According to a story from the Washington Post, the US Food and Drug Administration (FDA) has cleared the approval of Epidiolex®, a solution whose active ingredient is a refined version…

Continue Reading First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome